Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis.
Future Oncol
; 13(11): 1021-1034, 2017 May.
Article
en En
| MEDLINE
| ID: mdl-28088868
ABSTRACT
AIM:
To assess the prognostic values of Ki-67 in neoadjuvant setting for breast cancer patients.METHODS:
PubMed and EMBASE were searched. Revman software was used to conduct random-effect model meta-analysis.RESULTS:
49 studies (14,076 patients) were included. High Ki-67 before and after neoadjuvant chemotherapy were associated with worse overall survival (OS; before hazard ratio [HR] 2.29; 95% CI 1.42-3.69; after HR 2.24; 95% CI 1.82-2.75) and disease-free survival (DFS; before HR 1.54; 95% CI 1.23-1.95; after HR 2.08; 95% CI 1.83-2.37). Low/no reduction or increase might be associated with worse DFS (HR 2.13; 95% CI 1.51-3.02) and OS.CONCLUSION:
Ki-67 before and after neoadjuvant chemotherapy, as well as the change could predict the prognosis for breast cancer patients.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
6_breast_cancer
Asunto principal:
Neoplasias de la Mama
/
Biomarcadores de Tumor
/
Antígeno Ki-67
Tipo de estudio:
Prognostic_studies
/
Systematic_reviews
Límite:
Female
/
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2017
Tipo del documento:
Article
País de afiliación:
China